How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Within the oncology unit, sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased during the quarter. However, sales of key medicine Ibrance are expected to have been hurt due to continued competitive pressure across markets, generic entry and the Inflation Reduction Act ("IRA") impact in the United States.
With regard to ADC products, competitive pressure in the United States is likely to have hurt sales of Adcetris, while strong demand trends must have benefited Padcev's sales.
Our model estimates for second-quarter 2025 sales of the overall oncology segment are pegged at $4.0 billion, implying a 2% rise year over year.
Beyond oncology, Pfizer's top line is likely to have been aided by its key in-line products like Vyndaqel and Eliquis, alongside newer additions like Nurtec. However, this growth is expected to have been offset by the U.S. Medicare Part D headwinds and the continued declining sales of its COVID-19 products.
Competition in the Oncology Space
Other large players in the oncology space are AstraZeneca AZN and Merck MRK.
For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo).
Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 46% of Merck's total revenues in the first quarter of 2025.
PFE's Price Performance, Valuation and Estimates
Shares of Pfizer have underperformed the industry year to date, as shown in the chart below.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.25 times forward earnings, lower than 15.12 for the industry and the stock's 5-year mean of 10.86.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has declined from $3.08 to $3.05, while that for 2026 has gone up from $3.08 to $3.09 over the past 60 days.
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AstraZeneca PLC (AZN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Merck & Co., Inc. (MRK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
16 hours ago
- CTV News
JetBlue, United partnership gets go-ahead from U.S. Transportation Department
In this Oct. 18, 2019, file photo a JetBlue Airways flight flies in to Salt Lake City International Airport in Salt Lake City. (Rick Bowmer / AP Photo) JetBlue and United Airlines have cleared the U.S. Department of Transportation's review of their planned partnership which allows them to proceed with the implementation, the companies said on Tuesday. JetBlue had been seeking partnerships after a federal judge blocked its alliance with American Airlines in 2023. In May, JetBlue and United unveiled a partnership, dubbed 'Blue Sky,' that would allow travelers to book flights on both carriers' websites, while interchangeably earning and using points in their frequent flyer programs. Under the agreement, JetBlue would also provide United access to slots at the congested JFK International Airport at New York for up to seven daily round-trip flights, set to begin in 2027. The company said that the partnership is expected to contribute US$50 million more in incremental operating profit than it had initially planned. 'We believe Blue Sky will enable each airline to offer its customers access to hundreds of new flights and destinations through a traditional interline agreement,' said Marty St. George, JetBlue's president. Spirit Airlines in June had urged the U.S. transportation body to reject the collaboration between the two carriers, saying it was anticompetitive and would prompt other large carriers to pursue similar deals. Michael Ashley Schulman, chief investment officer at Running Point Capital, said by removing the antitrust triggers that led to the collapse of JetBlue's Northeast Alliance — such as shared revenue and joint scheduling — BlueSky has introduced a model that other mid-sized carriers could replicate with less risk of regulatory pushback. Antitrust officials under the Trump administration have been taking a more lenient approach to corporate deals, a shift from the stricter stance seen under Biden. In June, they approved several multibillion-dollar deals in just one week, signaling a greater willingness to settle with companies. More than 100 transactions have been granted shorter reviews this year, according to FTC data from July. JetBlue and United said that Blue Sky would begin introducing new customer benefits starting in fall 2025, rolling them out in phases. --- Reporting by Aishwarya Jain in Bengaluru and Doyinsola Oladipo in New York; Editing by Shailesh Kuber
National Post
20 hours ago
- National Post
BenchSci Expands Board of Directors with Appointment of Dr. Mikael Dolsten
Article content Industry Veteran and Former Pfizer Chief Scientific Officer Brings Extensive R&D and Leadership Experience to Advance BenchSci's Mission of Improving the Speed and Quality of Preclinical R&D Article content TORONTO — BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced that Mikael Dolsten, M.D., Ph.D., has joined its board of directors. Article content Dr. Dolsten, recently retired from Pfizer Inc., brings over three decades of extensive leadership and scientific expertise. During his 16-year tenure as Chief Scientific Officer and President of Pfizer Research & Development, Dr. Dolsten oversaw the regulatory approval of more than 36 medicines and vaccines. His efforts spearheaded advancements in drug discovery, with over 150 drug candidates progressing to clinical studies, and he played a vital role in the company's global response to the COVID-19 pandemic. Article content 'This is an incredible moment for BenchSci. We are honoured that Mikael has chosen to join us and lend his immense talent to our mission,' shared Liran Belenzon, CEO of BenchSci. 'Mikael's track record of leadership in pharmaceutical R&D will be invaluable as we continue to expand the reach of our AI-powered co-pilot for scientists. By helping R&D teams integrate generative AI into their workflows, we're enabling them to discover novel drug candidates faster and drive meaningful breakthroughs. Mikael's insights will be key in ensuring our technology makes a transformative impact on drug discovery.' Article content Dr. Dolsten's leadership experience spans some of the world's largest pharmaceutical organizations, including Wyeth Research, Boehringer Ingelheim, AstraZeneca, and Pharmacia. His remarkable career has been marked by contributions to approximately 50 drug and vaccine approvals, and through his VC experience, he's been involved in corporate transactions exceeding $100 billion in value. Article content 'BenchSci is doing something truly transformative with AI—redefining how we tackle preclinical research and speeding up drug discovery in ways I couldn't have imagined a decade ago,' said Mikael Dolsten, M.D., Ph.D. 'After spending my career immersed in pharmaceutical innovation, I'm inspired by the passion and vision of this team. Their work has the potential to solve some of the toughest challenges in R&D and, most importantly, bring life-saving treatments to patients faster. I'm thrilled to be part of this journey.' Article content Beyond his executive leadership roles, Dr. Dolsten has held influential positions on several public and private boards, including Agilent Technologies, Rocket Pharmaceuticals, Orbis Medicine, and Arbor Biotechnologies. Additionally, he serves as an investment advisor to leading organizations such as Blackstone Life Sciences, Google's GV, and Bain & Company. His advisory roles extend to public health initiatives, where he has collaborated with U.S. and U.K. governments and served organizations like the Scripps Research Institute and the Foundation for the NIH. Article content Since its inception, BenchSci has pioneered the application of AI through its platform, ASCEND, which acts as a scalable AI assistant for preclinical scientists. ASCEND transforms preclinical R&D by decoding biomedical research, multi-omics data, and integrating it with proprietary customer data. This creates an unbiased map of the underlying disease biology, empowering scientists to discover novel insights and accelerate R&D. ASCEND supports core functions from target identification to experimental design, validation, and translational workflows, increasing productivity. By streamlining preclinical research and prioritizing the most promising experiments, ASCEND accelerates the path to life-saving treatments. Article content BenchSci remains steadfast in its mission to solve the number one reason drug discovery projects fail—getting the biology wrong. Article content BenchSci is a world leader in AI solutions for drug discovery on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. Our platform, ASCEND, acts as a scalable AI assistant for preclinical organizations, increasing the productivity of the preclinical R&D pipeline across therapeutic areas. Backed by top-tier investors, including Generation, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google's AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. We're a Deloitte Technology Fast 50™ and Fast 500™ winner and a certified Great Place to Work®. For more information about BenchSci, visit Article content Article content Article content Article content
National Post
20 hours ago
- National Post
Alpha Cognition Announces Partner China Medical System Has NDA Accepted in China for the Review of ZUNVEYL® (Benzgalantamine) for Alzheimer's Disease
Article content VANCOUVER, British Columbia & DALLAS — Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' [ACI], or the 'Company'), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer's dementia. Article content 'We are pleased to announce the NMPA acceptance of the ZUNVEYL New Drug Application, marking a significant milestone in our mission to bring innovative treatments to patients in need,' said Michael McFadden, Chief Executive Officer of Alpha Cognition. 'This acceptance reflects the strength of our partnership with CMS and the dedication of our team. We look forward to working closely with our partner throughout this important review process as we move one step closer to potentially delivering this important therapy to the Asia market.' Article content Alpha Cognition will rely on successful regulatory and commercial expertise of CMS in the Chinese market and will benefit financially from advances in China and other Asia territories. The Company is eligible to receive regulatory, sales milestones, and royalties should ZUNVEYL be approved for marketing in China and other Asia territories. Article content According to the epidemiological study results published in the Lancet Public Health, there are about 7.93 million patients with mild-to-moderate Alzheimer dementia in China. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future. The Company anticipates additional progress across other countries with regulatory advancement and ZUNVEYL commercial approvals. Article content About Alpha Cognition Inc. Article content Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. Article content ALPHA-1062 (benzgalantamine) formulated as a delayed release oral tablet (ZUNVEYL ®), is FDA approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as a sublingual formulation for cognitive Impairment with mTBI. Article content ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. Article content IMPORTANT SAFETY INFORMATION Article content CONTRAINDICATIONS Article content ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. Article content WARNINGS AND PRECAUTIONS Article content Serious Skin Reactions Article content : Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Article content Anesthesia Article content : See Drug Interactions Section Article content Cardiovascular Conditions: Article content Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Article content Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Article content Gastrointestinal Conditions Article content : Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Article content Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Article content Genitourinary Conditions: Article content Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Article content Neurological Conditions: Article content Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Article content Pulmonary Conditions: Article content Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. Article content ADVERSE REACTIONS Article content The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. Article content DRUG INTERACTIONS Article content Use with Anticholinergics: Article content Galantamine has the potential to interfere with the activity of anticholinergic medications. Article content Use with Cholinomimetics and Other Cholinesterase Inhibitors: Article content A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. Article content USE IN SPECIFIC POPULATIONS Article content Pregnancy: Article content Based on animal data may cause fetal harm. Article content Hepatic Impairment: Article content In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Article content Renal Impairment: Article content In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. Article content These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Article content Forward-looking Statements Article content This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential benefits of the licensing agreement for the development and commercialization of ZUNVEYL in Asia (excluding Japan), Australia and New Zealand, the Company's timing and planned activities to launch ZUNVEYL in the U.S. and China, the timing for the Company's planned corporate update call, the potential timing for the availability of ZUNVEYL in the U.S. and China, the potential future developments of ZUNVEYL in China, the potential market size for ZUNVEYL in China, the Company's business strategy for the launch of ZUNVEYL in China, the market size and demand for ZUNVEYL in China, the Company's potential growth opportunities in China, the timing and results of the Company's milestone payments for China, the Company's regulatory submissions in China, and the potential regulatory approval and commercialization of the Company's products in China. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's Form S-1/A registration statement as filed with the SEC on November 6, 2024 and available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law. Article content Article content Article content Article content
